KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Amneal Pharmaceuticals (AMRX) Dividends Paid - Common (2017 - 2018)

Amneal Pharmaceuticals has reported Dividends Paid - Common over the past 2 years, most recently at $153.0 million for Q2 2018.

For Q2 2018, Dividends Paid - Common changed N/A year-over-year to $153.0 million; the TTM value through Mar 2019 reached $153.0 million, changed N/A, while the annual FY2018 figure was $183.0 million, 51.23% down from the prior year.
Dividends Paid - Common for Q2 2018 was $153.0 million at Amneal Pharmaceuticals, up from $30.0 million in the prior quarter.
Over five years, Dividends Paid - Common peaked at $153.0 million in Q2 2018 and troughed at $20.0 million in Q4 2017.